TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent

Trial Profile

TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Apr 2014

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Coronary disorders; Myocardial infarction; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms TAXUS-IV
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 23 Apr 2014 Data cleaning 4: Deleted descriptors - Drug-eluting-stents (non drug), Controlled-release-drugs (delivery system), coronary-stenting (non drug procedure), GPIIb-IIIa-antagonists (drug class), cost-effectiveness, cost-utility, Ischaemia etc.
    • 25 Sep 2008 FDA approval received for TAXUS stent.
    • 22 Oct 2007 Boston Scientific announced final 5-year follow-up data.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top